Last checked at 16 Sep 2014 07:00
For immediate release | 16 September 2014 |
Futura Medical plc
("Futura" or "the Company")
Grant of Options
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that on 12 September 2014 it granted options over a total of 580,000 ordinary shares of 0.2p each in the Company to Directors as detailed below.
Director | Number of options granted | Exercise price | Exercise period | Total number of options held following notification | Total number of ordinary shares held |
|
|
|
|
|
|
J H Barder | 250,000 | 51.75p | 1 Oct 2016 - 30 Sep 2021 | 1,250,000 | 1,008,830 |
D B Davies | 200,000 | 51.75p | 1 Oct 2016 - 30 Sep 2021 | 980,000 | 751,306 |
D A Martin | 130,000 | 51.75p | 1 Oct 2016 - 30 Sep 2021 | 719,279 | 280,000 |
All options were granted under the Futura Medical plc Unapproved Share Option Scheme with the exception of 103,961 options granted to D A Martin which were granted under the Futura Medical plc Enterprise Management Incentive Scheme.
The main vesting condition of the options is that the Directors remain employed with the Company as at the date of exercise.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive | Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nominated Adviser: |
|
N+1 Singer Aubrey Powell / Thomas Smale | Tel:+44 (0)20 7496 3000 |
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com